Literature DB >> 20489146

CNS-expressed cathepsin D prevents lymphopenia in a murine model of congenital neuronal ceroid lipofuscinosis.

Zinayida Shevtsova1, Manuel Garrido, Jochen Weishaupt, Paul Saftig, Mathias Bähr, Fred Lühder, Sebastian Kügler.   

Abstract

Deficiency in Cathepsin D (CtsD), the major cellular lysosomal aspartic proteinase, causes the congenital form of neuronal ceroid lipofuscinoses (NCLs). CtsD-deficient mice show severe visceral lesions like lymphopenia in addition to their central nervous system (CNS) phenotype of ceroid accumulation, microglia activation, and seizures. Here we demonstrate that re-expression of CtsD within the CNS but not re-expression of CtsD in visceral organs prevented both central and visceral pathologies of CtsD(-/-) mice. Our results suggest that CtsD was substantially secreted from CNS neurons and drained from CNS to periphery via lymphatic routes. Through this drainage, CNS-expressed CtsD acts as an important modulator of immune system maintenance and peripheral tissue homeostasis. These effects depended on enzymatic activity and not on proposed functions of CtsD as an extracellular ligand. Our results furthermore demonstrate that the prominent accumulation of ceroid/lipofuscin and activation of microglia in brains of CtsD(-/-) are not lethal factors but can be tolerated by the rodent CNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489146      PMCID: PMC2893670          DOI: 10.2353/ajpath.2010.091267

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice.

Authors:  Masato Koike; Masahiro Shibata; Yoshiyuki Ohsawa; Hiroshi Nakanishi; Tomoyuki Koga; Satoshi Kametaka; Satoshi Waguri; Takashi Momoi; Eiki Kominami; Christoph Peters; Kurt von Figura; Paul Saftig; Yasuo Uchiyama
Journal:  Mol Cell Neurosci       Date:  2003-02       Impact factor: 4.314

Review 2.  Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance.

Authors:  H F Cserr; C J Harling-Berg; P M Knopf
Journal:  Brain Pathol       Date:  1992-10       Impact factor: 6.508

3.  A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells.

Authors:  M Glondu; P Coopman; V Laurent-Matha; M Garcia; H Rochefort; E Liaudet-Coopman
Journal:  Oncogene       Date:  2001-10-18       Impact factor: 9.867

4.  Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice.

Authors:  H Nakanishi; J Zhang; M Koike; T Nishioku; Y Okamoto; E Kominami; K von Figura; C Peters; K Yamamoto; P Saftig; Y Uchiyama
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

5.  A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration.

Authors:  J Tyynelä; I Sohar; D E Sleat; R M Gin; R J Donnelly; M Baumann; M Haltia; P Lobel
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

6.  Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10).

Authors:  Karen Fritchie; Eija Siintola; Diane Armao; Anna-Elina Lehesjoki; Thomas Marino; Cynthia Powell; Michael Tennison; Jessica M Booker; Sabine Koch; Sanna Partanen; Kinuko Suzuki; Jaana Tyynelä; Leigh B Thorne
Journal:  Acta Neuropathol       Date:  2008-09-02       Impact factor: 17.088

7.  Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions.

Authors:  Mustapha Lkhider; Roberta Castino; Edwige Bouguyon; Ciro Isidoro; Michèle Ollivier-Bousquet
Journal:  J Cell Sci       Date:  2004-10-01       Impact factor: 5.285

8.  Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation.

Authors:  M Heinrich; J Neumeyer; M Jakob; C Hallas; V Tchikov; S Winoto-Morbach; M Wickel; W Schneider-Brachert; A Trauzold; A Hethke; S Schütze
Journal:  Cell Death Differ       Date:  2004-05       Impact factor: 15.828

9.  Procathepsin D interacts with prosaposin in cancer cells but its internalization is not mediated by LDL receptor-related protein.

Authors:  Valérie Laurent-Matha; Annick Lucas; Silke Huttler; Konrad Sandhoff; Marcel Garcia; Henri Rochefort
Journal:  Exp Cell Res       Date:  2002-07-15       Impact factor: 3.905

10.  Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis.

Authors:  Guy Berchem; Murielle Glondu; Michel Gleizes; Jean-Paul Brouillet; Françoise Vignon; Marcel Garcia; Emmanuelle Liaudet-Coopman
Journal:  Oncogene       Date:  2002-08-29       Impact factor: 9.867

View more
  17 in total

1.  Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.

Authors:  André R A Marques; Alessandro Di Spiezio; Niklas Thießen; Lina Schmidt; Joachim Grötzinger; Renate Lüllmann-Rauch; Markus Damme; Steffen E Storck; Claus U Pietrzik; Jens Fogh; Julia Bär; Marina Mikhaylova; Markus Glatzel; Mahmoud Bassal; Udo Bartsch; Paul Saftig
Journal:  Autophagy       Date:  2019-07-16       Impact factor: 16.016

2.  Lack of Cathepsin D in the central nervous system results in microglia and astrocyte activation and the accumulation of proteinopathy-related proteins.

Authors:  Chigure Suzuki; Junji Yamaguchi; Takahito Sanada; Juan Alejandro Oliva Trejo; Souichirou Kakuta; Masahiro Shibata; Isei Tanida; Yasuo Uchiyama
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

3.  Dopamine and its metabolites in cathepsin D heterozygous mice before and after MPTP administration.

Authors:  Donna Crabtree; Michaël Boyer-Guittaut; Xiaosen Ouyang; Naomi Fineberg; Jianhua Zhang
Journal:  Neurosci Lett       Date:  2013-02-04       Impact factor: 3.046

Review 4.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

Review 5.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

6.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

Review 7.  Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function.

Authors:  Amanda L Getty; David A Pearce
Journal:  Cell Mol Life Sci       Date:  2010-08-01       Impact factor: 9.207

8.  Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.

Authors:  Susy Prieto Huarcaya; Alice Drobny; André R A Marques; Alessandro Di Spiezio; Jan Philipp Dobert; Denise Balta; Christian Werner; Tania Rizo; Lisa Gallwitz; Simon Bub; Iva Stojkovska; Nandkishore R Belur; Jens Fogh; Joseph R Mazzulli; Wei Xiang; Amitkumar Fulzele; Mario Dejung; Markus Sauer; Beate Winner; Stefan Rose-John; Philipp Arnold; Paul Saftig; Friederike Zunke
Journal:  Autophagy       Date:  2022-04-28       Impact factor: 13.391

9.  The induction of neuronal death by up-regulated microglial cathepsin H in LPS-induced neuroinflammation.

Authors:  Kai Fan; Daobo Li; Yanli Zhang; Chao Han; Junjie Liang; Changyi Hou; Hongliang Xiao; Kazuhiro Ikenaka; Jianmei Ma
Journal:  J Neuroinflammation       Date:  2015-03-19       Impact factor: 8.322

10.  Overexpression of BDNF increases excitability of the lumbar spinal network and leads to robust early locomotor recovery in completely spinalized rats.

Authors:  Ewelina Ziemlińska; Sebastian Kügler; Melitta Schachner; Iwona Wewiór; Julita Czarkowska-Bauch; Małgorzata Skup
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.